Need an original paper?
Buy Essay Now
Research Database of Quotes
It is sometimes difficult to be inspired when trying to write a persuasive essay, book report or thoughtful research paper. Often of times, it is hard to find words that best describe your ideas. Paper-Research now provides a database of over 150,000 quotations and proverbs from the famous inventors, philosophers, sportsmen, artists, celebrities, business people, and authors that are aimed to enrich and strengthen your essay, term paper, book report, thesis or research paper.
Try our free search of constantly updated quotations and proverbs database.
Browse Authors
(Click a letter to view the authors)
Al Rauch Quotes
«It seems like it's not really a major association,»
Author: Al Rauch
«They both could be key products.»
Author: Al Rauch
«People who are more science-oriented and innovative tend to look down on me-too drugs, ... there's a lot more risk in being innovative.»
Author: Al Rauch
«Dragging your 10-year-old to get a vaccine for a sexually transmitted disease could have some groups pretty upset.»
Author: Al Rauch
«It's certainly a major medical need in the ability to prevent cervical cancer. That gives it the potential to be a blockbuster. We're not expecting a real quick ramp up on this, though it could become a billion dollar drug.»
Author: Al Rauch
«It was not your typical Pfizer conference call,»
Author: Al Rauch
«You just can't grow the top line. I view Pfizer as a duck. They're floating and it looks easy, but they're paddling like crazy underneath.»
Author: Al Rauch
«We think it might make sense for them to try and focus on what they do well, which is Phase III testing and marketing,»
Author: Al Rauch
«There were some people who were giving it only a 50-50 chance [Pfizer] would win. We thought it was a big probability that they'd win. It's not a surprise the stock is moving up. A lot of value investors were on the sidelines, because they just don't buy things that have a huge risk in front of them.»
Author: Al Rauch
«We've seen [generic challengers'] success rate go down dramatically over last year. The drug companies are getting more experienced at defending these challenges.»
Author: Al Rauch